Acceleron

Acceleron's PAH drug gets the FDA's red carpet treatment with breakthrough status
Endpoints
Wed, 04/8/20 - 10:37 am
Acceleron
PAH
FDA
breakthrough therapy
sotatercept
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS
Pharmaceutical Business Review
Mon, 04/6/20 - 10:30 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
MDS
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
FDA
regulatory
Bristol-Myers Squibb
ozanimod
Esteve
E-58425
Fabre-Kramer
AstraZeneca
Imfinzi
Astellas
Vesicare
AbbVie
Neurocrine
Orlissa
Sanofi
MenQuadfi
opicapone
Acceleron
Reblozyl
Acceleron ditches midstage drug after flop
Fierce Biotech
Tue, 03/10/20 - 10:38 am
Acceleron
Charcot-Marie-Tooth
clinical trials
ACE-083
Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Disease
Motley Fool
Sun, 02/23/20 - 06:17 pm
beta thalassemia
rare disease
drug development
Acceleron
Bristol-Myers Squibb
Bluebird Bio
Sangamo Therapeutics
Vertex Pharmaceuticals
Editas Medicine
Syros Pharmaceuticals
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Tue, 01/28/20 - 11:09 am
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Acceleron Shares Surge as Its Hypertension Drug Meets Trial Endpoints
Motley Fool
Mon, 01/27/20 - 10:47 pm
Acceleron
PAH
clinical trials
sotatercept
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Pharmaceutical Business Review
Wed, 01/1/20 - 06:51 pm
Acceleron
Fulcrum Therapeutics
R&D
small molecule drugs
pulmonary
Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS
Pharmaceutical Business Review
Wed, 12/4/19 - 10:34 am
Bristol-Myers Squibb
Acceleron
FDA
Reblozyl
myelodysplastic syndromes
FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease
BioSpace
Sat, 11/9/19 - 12:13 pm
Celgene
Acceleron
Reblozyl
anemia
beta thalassemia
Another failed midstage asset for Acceleron, another pipeline test dumped
Fierce Biotech
Tue, 09/17/19 - 10:19 am
Acceleron
clinical trials
ACE-083
Acceleron gets FDA orphan drug designation for sotatercept in pulmonary arterial hypertension
Pharmaceutical Business Review
Tue, 09/10/19 - 11:06 am
Acceleron
orphan drugs
sotatercept
PAH
In a much-needed positive for BMS, Celgene gains FDA review for blockbuster hopeful
Fierce Biotech
Tue, 06/4/19 - 11:02 am
Celgene
Bristol-Myers Squibb
Acceleron
luspatercept
MDS
beta thalassemia
Celgene and Acceleron Submit BLA for Luspatercept
CP Wire
Fri, 04/5/19 - 11:44 am
Celgene
Acceleron
luspatercept
myelodysplastic syndrome
beta thalassemia
Celgene and Acceleron Submit BLA for Luspatercept
Fri, 04/5/19 - 10:44 am
Celgene
Acceleron
luspatercept
Acceleron, Stemline price upsized follow-ons
BioCentury
Wed, 01/16/19 - 11:57 am
Acceleron
Stemline Therapeutics
Celgene
Elzonris tagraxofusp-erzs
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Fri, 01/11/19 - 09:58 am
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
BMS deal weighs on Celgene partners
BioCentury
Thu, 01/3/19 - 11:45 pm
M&A
Celgene
Bristol-Myers Squibb
Acceleron
BeiGene
Top Biotech Stocks to Watch at ASH 2018
Yahoo/Motley Fool
Sun, 12/2/18 - 12:37 pm
ASH2018
Celgene
Bluebird Bio
Acceleron
3 Cancer Stocks to Watch in December
Motley Fool
Wed, 11/7/18 - 10:06 am
Acceleron
luspatercept
Bluebird Bio
bb21217
Amgen
AMG 420

Pages